Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DIM-3,5 refers to a series of 1,1-bis(3′-indolyl)-1-(3,5-disubstitutedphenyl)methane analogs that act as potent anticancer agents. These compounds function as dual inverse agonists of the orphan nuclear receptors NR4A1 (Nur77) and NR4A2 (Nurr1). In glioblastoma (GBM) research, DIM-3,5 analogs have demonstrated the ability to downregulate the expression of O6-methylguanine-DNA methyltransferase (MGMT), a key enzyme associated with resistance to the alkylating chemotherapy temozolomide (TMZ). By inhibiting the transcriptional regulation of MGMT mediated by NR4A1, NR4A2, and Sp1, these analogs reduce MGMT mRNA and protein levels, potentially sensitizing resistant glioblastoma phenotypes to standard-of-care treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DIM-3,5.